证券代码：688382 证券简称：益方生物 公告编号：2023-026 （二）审议通过《关于公司 2023 年半年度募集资金存放与实际使用情况的 专项报告的议案》 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）及 指定媒体的《益方生物科技（上海）股份有限公司 2023 年半年度募集资金存放 与实际使用情况的专项报告》（公告编号：2023-028）。 益方生物科技（上海）股份有限公司 第一届董事会 2023 年第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 益方生物科技（上海）股份有限公司（以下简称"公司"）第一届董事会 2023 年第四次会议于 2023 年 8 月 21 日以现场结合通讯形式召开，本次会议通 知已于 2023 年 8 月 16 日以书面形式发出。会议应出席董事 8 名，实际出席董事 8名，公司高级管理人员列席本次会议。本次会议的召集、召开程序符合《中华 人民共和国公司法》及《益方生物科技（上海）股份有限公司章程》的有关规 定。公司董 ...

上海信公轶禾企业管理咨询有限公司 关于 益方生物科技（上海）股份有限公司 2022 年限制性股票激励计划 预留授予相关事项 上海信公轶禾企业管理咨询有限公司 独立财务顾问报告 之 独立财务顾问报告 独立财务顾问： 二〇二三年八月 上海信公轶禾企业管理咨询有限公司 独立财务顾问报告 目 录 | 第一章 | 声 明 3 | | --- | --- | | 第二章 | 释 义 5 | | 第三章 | 基本假设 7 | | 第四章 | 本激励计划履行的审批程序 8 | | 第五章 | 本次限制性股票的授予情况 10 | | | 一、限制性股票预留授予的具体情况 10 | | | 二、本次预留部分限制性股票授予与股东大会审议通过的激励计划的差异情况 12 | | 第六章 | 本次限制性股票授予条件说明 13 | | | 一、限制性股票授予条件 13 | | | 二、董事会对授予条件成就的情况说明 13 | | 第七章 | 独立财务顾问的核查意见 15 | 2 第一章 声 明 上海信公轶禾企业管理咨询有限公司接受委托，担任益方生物科技（上 海）股份有限公司（以下简称"益方生物"、"上市公司"或"公司"）2022 年限制 ...

证券代码：688382 证券简称：益方生物 公告编号：2023-030 益方生物科技（上海）股份有限公司 关于向 2022 年限制性股票激励计划激励对象授予预 留部分限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 《益方生物科技（上海）股份有限公司 2022 年限制性股票激励计划》（以 下简称"《激励计划》"或"本激励计划"）规定的益方生物科技（上海）股份有 限公司（以下简称"公司"）2022年限制性股票预留部分授予条件已经成就，根 据公司 2023 年第一次临时股东大会授权，公司于 2023 年 8 月 21 日召开第一届 董事会 2023 年第四次会议、第一届监事会 2023 年第三次会议，分别审议通过 了《关于向 2022 年限制性股票激励计划激励对象授予预留部分限制性股票的议 案》，确定 2023 年 8 月 21 日为预留授予日，以 4.35 元/股的授予价格向 2 名激励 对象授予 68,824 股限制性股票。现将有关事项说明如下： 一、限制性股票授予情况 （一）本次限制性股票 ...

中国上海石门一路 288 号 兴业太古汇香港兴业中心一座 26 层 邮编：200041 电话：（86-21）5298 5488 传真：（86-21）5298 5492 君合律师事务所上海分所 关于益方生物科技（上海）股份有限公司 2022 年限制性股票激励计划授予预留部分限制性股票事项的 法律意见书 益方生物科技（上海）股份有限公司： 君合律师事务所上海分所（以下简称"本所"）接受益方生物科技（上海）股份 有限公司（以下简称"公司"或"上市公司"或"益方生物"）的委托，作为公司 2022 年限制性股票激励计划（以下简称"本次激励计划"）的特聘专项法律顾问，根据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以 下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理办法》"）、 《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、《科创板 上市公司自律监管指南第 4 号——股权激励信息披露》（以下简称"《自律监管指 南》"）等中国现行法律、法规和规范性文件（为本法律意见书之目的，"中国现行 法律、法规和规范性文件"不包括香港特别行政区、澳门特别行政区 ...

重要内容提示： 会议召开时间：2023 年 6 月 5 日(星期一) 下午 13:00-14:00 证券代码：688382 证券简称：益方生物 公告编号： 2023-017 益方生物科技（上海）股份有限公司 关于召开 2022 年度业绩说明会的公告 公司已于 2023 年 4 月 26 日发布公司 2022 年度报告，为便于广 大投资者更全面深入地了解公司 2022 年度经营成果、财务状况，公 司计划于 2023 年 6 月 5 日下午 13:00-14:00 举行 2022 年度业绩说 明会，就投资者关心的问题进行交流。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 5 月 29 日（星期一）至 6 月 2 日（星期五） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过 益方生物科技（上海）股份有限公司（以下简称"公司"）邮箱 ir@inventisbio.com 进行提问。公司将在说明会上对投资者普遍关 注的问题进行回答。 会议召开地点： ...

Financial Performance - The net loss attributable to the parent company for 2022 was CNY 483 million, with a cumulative unabsorbed loss of CNY 2.021 billion[4]. - The company reported a significant increase in revenue, reaching RMB 500 million, representing a 25% year-over-year growth[25]. - The company's net profit attributable to shareholders was -483,485,014.66 RMB in 2022, a decrease from -357,911,474.59 RMB in 2021, representing an increase in loss of approximately 35%[26]. - The weighted average return on equity was -37.63% in 2022, an improvement from -42.22% in 2021[27]. - The net cash flow from operating activities was -476,894,087.23 RMB in 2022, worsening from -252,066,024.95 RMB in 2021[26]. - The company reported a net loss attributable to shareholders of RMB 483 million for the reporting period, an increase of RMB 126 million compared to the same period last year, primarily due to increased R&D expenses as products entered critical registration clinical trial phases[154]. Research and Development - Research and development expenses for the year were CNY 461 million, representing a year-on-year increase of 46.49%[4]. - The company has multiple drug development projects in progress, with all products currently in the research and development stage and no commercial sales yet[5]. - The company plans to increase its R&D budget by 30% to support ongoing and future projects[25]. - The company has established partnerships with three leading research institutions to accelerate drug development timelines[25]. - The company’s R&D expenses have increased, contributing to the net loss, as it accelerates clinical research progress[27]. - The company has invested RMB 50 million in new technology for drug development, aiming to improve efficiency by 40%[25]. - The company aims to enhance its innovation capabilities and product development to adapt to changing market rules and regulatory policies[147]. Product Pipeline and Clinical Trials - The product pipeline includes BPI-D0316, which has completed registration clinical trials for non-small cell lung cancer and is currently under review by the National Medical Products Administration (NMPA)[5]. - The company has one product in the NDA stage and four products in clinical trials, with three products approved for Phase II or III clinical trials[37]. - D-1553, a KRAS G12C inhibitor, is the first of its kind in China to enter clinical trials and is currently in Phase II trials[40]. - D-0502, an oral selective estrogen receptor degrader, has commenced Phase III clinical trials for ER-positive, HER2-negative breast cancer[41]. - D-2570, a novel oral selective TYK2 inhibitor for psoriasis, received approval to start Phase I clinical trials in June 2022[43]. - The company aims to advance more preclinical candidates into clinical trials and enrich its product pipeline in the future[47]. - The company has multiple ongoing clinical projects, including D-2570 for psoriasis and other undisclosed projects targeting tumors[50]. Market Strategy and Expansion - The company emphasizes the importance of market expansion and academic promotion for new drug acceptance post-approval[7]. - The company is expanding its market presence in Europe, targeting a 15% market share within the next two years[25]. - The company plans to adopt a combination of licensing cooperation and self-sales for product commercialization as products enter the market[72]. - The company aims to capture new drug targets and technologies to enrich its preclinical pipeline, with expectations of entering one to two products into clinical trials annually over the next three years[189]. Risks and Challenges - The company faces risks related to not being profitable, with a long cycle for drug development and significant funding requirements[5]. - There is uncertainty regarding the entry of products into the National Medical Insurance Directory, which could affect price competitiveness[8]. - The company relies on third-party CMO for the production of clinical and preclinical products, which introduces quality control risks[8]. - The company is exposed to foreign exchange risks due to international clinical trials conducted in various currencies, which may negatively impact R&D costs[146]. - The company must navigate complex regulatory environments in different countries, which can affect the approval and commercialization of its products[148]. - The company is at risk of not securing adequate intellectual property protection for its research drugs, which could allow competitors to develop similar products[149]. Corporate Governance - The company held 1 annual general meeting and 1 extraordinary general meeting during the reporting period, ensuring compliance with legal requirements and protecting the rights of minority shareholders[194]. - The board of directors consists of 9 members, including 3 independent directors, and held 8 meetings during the reporting period, approving all agenda items[194]. - The supervisory board comprises 3 members, including 2 employee supervisors, and convened 4 meetings, approving all agenda items[195]. - All resolutions from the shareholder meetings were passed without any objections, indicating effective governance and decision-making processes[198].

Financial Performance - Total revenue for Q1 2023 was not applicable as all products are still in the research and development stage[8]. - Net loss attributable to shareholders for Q1 2023 was ¥117,870,350.59, with a net profit excluding non-recurring items of ¥119,811,770.67[5]. - Basic and diluted earnings per share for Q1 2023 were both -¥0.20[6]. - The weighted average return on equity for Q1 2023 was -5.24%[6]. - Total operating costs for Q1 2023 were CNY 119,810,412.20, a slight decrease of 0.14% compared to CNY 119,984,869.48 in Q1 2022[17]. - Net loss for Q1 2023 was CNY 117,870,350.59, an improvement of 1.68% from a net loss of CNY 119,878,249.53 in Q1 2022[19]. - Other comprehensive income for Q1 2023 was CNY 419,135.55, compared to a loss of CNY 136,957.90 in Q1 2022[20]. - Basic and diluted earnings per share for Q1 2023 were both CNY -0.20, an improvement from CNY -0.26 in Q1 2022[20]. Assets and Liabilities - Total assets at the end of Q1 2023 were ¥2,245,806,646.19, a decrease of 4.09% from the end of the previous year[6]. - As of March 31, 2023, the total current assets amounted to RMB 2,171,277,840.55, a decrease from RMB 2,265,470,912.30 as of December 31, 2022, reflecting a decline of approximately 4.2%[15]. - The total assets as of March 31, 2023, were RMB 2,245,806,646.19, down from RMB 2,341,609,014.39, marking a decrease of about 4.1%[16]. - The non-current assets totaled RMB 74,528,805.64, a decrease from RMB 76,138,102.09, reflecting a decline of approximately 2.1%[15]. - The total liabilities increased to RMB 133,131,287.51 from RMB 126,686,902.60, indicating a rise of approximately 5.4%[16]. - The company's retained earnings showed a negative balance of RMB -2,138,616,910.69, worsening from RMB -2,020,746,560.10[16]. - The total equity attributable to shareholders decreased to RMB 2,112,675,358.68 from RMB 2,214,922,111.79, a decline of about 4.6%[16]. Cash Flow - The company reported a net cash flow from operating activities of -¥81,674,325.83 for Q1 2023[5]. - Net cash flow from operating activities for Q1 2023 was CNY -81,674,325.83, compared to CNY -99,873,889.37 in Q1 2022, indicating a reduced cash outflow[21]. - Cash and cash equivalents decreased to RMB 1,645,819,421.57 from RMB 2,235,210,918.84, representing a significant drop of about 26.4%[14]. - Cash and cash equivalents at the end of Q1 2023 were CNY 1,645,819,421.57, up from CNY 615,149,649.24 at the end of Q1 2022[22]. - Investment activities resulted in a net cash outflow of CNY 501,958,351.88 in Q1 2023, compared to CNY -2,109,829.64 in Q1 2022[21]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,680[10]. - The largest shareholder, InventisBio Hong Kong Limited, held 19.19% of the shares, totaling 110,329,937 shares[11]. Research and Development - Research and development expenses for Q1 2023 totaled ¥110,164,964.97, representing 2.31% of total revenue[6]. - The company incurred research and development expenses of CNY 110,164,964.97 in Q1 2023, slightly up from CNY 107,678,795.28 in Q1 2022[17].

2022 年第三季度报告 单位：元 币种：人民币 1 / 12 证券代码：688382 证券简称：益方生物 益方生物科技（上海）股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期比 年初至报告期 | --- | --- | --- | --- | --- | |------------------------------------------------|-----------------|---------------------------|-----------------|------------------- ...